Last reviewed · How we verify
Inj. Octreotide
Inj. Octreotide is a Somatostatin analog Small molecule drug developed by PVS Memorial Hospital. It is currently FDA-approved for Acromegaly, Variceal bleeding in portal hypertension, Carcinoid syndrome. Also known as: Inj Octride.
Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels, inhibiting the release of various hormones and reducing blood flow to tumors.
Inj. Octreotide is a protein-based medication used to treat conditions such as Acromegaly, Neuroendocrine Tumors, and Pancreatic Fistula. It is administered via injection and works by binding to specific proteins, although the exact mechanism is not specified in the provided information.
At a glance
| Generic name | Inj. Octreotide |
|---|---|
| Also known as | Inj Octride |
| Sponsor | PVS Memorial Hospital |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and vascular tissue. This binding suppresses the secretion of growth hormone, insulin, and other hormones, and reduces splanchnic blood flow. These effects make it useful in controlling hormone-related symptoms and slowing tumor growth in neuroendocrine malignancies.
Approved indications
- Acromegaly
- Variceal bleeding in portal hypertension
- Carcinoid syndrome
- VIPoma
- Gastrinoma
- Neuroendocrine tumors
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Hyperglycemia
- Cholelithiasis
- Injection site pain
Key clinical trials
- Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (PHASE2)
- Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inj. Octreotide CI brief — competitive landscape report
- Inj. Octreotide updates RSS · CI watch RSS
- PVS Memorial Hospital portfolio CI
Frequently asked questions about Inj. Octreotide
What is Inj. Octreotide?
How does Inj. Octreotide work?
What is Inj. Octreotide used for?
Who makes Inj. Octreotide?
Is Inj. Octreotide also known as anything else?
What drug class is Inj. Octreotide in?
What development phase is Inj. Octreotide in?
What are the side effects of Inj. Octreotide?
What does Inj. Octreotide target?
Related
- Drug class: All Somatostatin analog drugs
- Target: All drugs targeting Somatostatin receptors (SSTR2, SSTR5)
- Manufacturer: PVS Memorial Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acromegaly
- Indication: Drugs for Variceal bleeding in portal hypertension
- Indication: Drugs for Carcinoid syndrome
- Also known as: Inj Octride
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing